The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
|Webcasts|November 11, 2021
The Next Generation Central Lab
Author(s)Frontage Labs
Now Available On Demand! The Next Generation Central Lab is on its way. Frontage Laboratories Inc explains how it envisions the next-generation central lab and what it will take to get there.
Register free
Event Overview:
A client-centered ‘Next Generation Central Lab,’ is a central lab that offers clinical laboratory testing, biorepository, logistics, and data management services through complete automation and optimized alignment and connectivity between operation, project management, QA, business development, finance, and information systems. The overall goal is to focus on clients’ needs and the ultimate success of the clinical trial study.
Dr. Nan Zhang, VP of Global Central Lab Services at Frontage Laboratories Inc., will provide a valuable update on the changes and current challenges in the central lab space, as well as how the ‘Next Generation Central Lab’ can add value to clinical trial studies.
Key Learning Objectives:
- What have been the changes in the central lab space
- Current challenges in global central labs
- The concept of ‘Next Generation Central Lab’ and how it can add value to the clinical trials
Who Should Attend:
- Clinical Trial Study Sponsor Executives
- Laboratory leadership
Speakers
Nan Zhang MD PhD
VP, Global Central Lab Services
Frontage Laboratories, Inc
Dr. Nan Zhang is an Anatomic Pathology, Clinical Pathology, and Hematology Board-certified Pathologist with over 20 years of experience in Clinical Laboratory Medicine and Biomedical Research. She provides leadership and strategic direction to global central laboratories at Frontage Laboratories, Inc., and is responsible for global quality, patient safety, regulatory compliance, operational excellence, process improvement, and organizational structure.
Before joining Frontage, Dr. Zhang served as the Medical Director at ACM Global Laboratories, and Director of Hematology, Flow Cytometry, Advanced Coagulation, and Blood Bank at Rochester General Hospital. From 2018 to 2019, she served as the President at the Western New York Society of Pathologists.
Register free:
Related to this article
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes.
The FDA’s RTCT initiative transmits predefined, clinically meaningful signals to regulators during active trials, so its value depends entirely on the maturity of sponsors’ upstream RBQM signal intelligence, KRIs, QTLs, and root-cause context, rather than on data speed.
In this video interview, Kent Thoelke, CEO of Paradigm Health, outlines why anti-kickback guidance and modern EHR-integrated trial matching technology must work in tandem to reach representative patient populations at the community level.
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without
4
Closing the Medical Writing Capacity Gap: Why Training Beats Technology
5